The growing pharmaceutical infrastructure in these emerging markets is spurring the demand for high-purity water systems, creating opportunity for water management companies. In addition, many developed and developing nations are imposing stringent effluent standards on the wastewater discharged from drug manufacturing facilities in order to prevent contamination of water streams.
New analysis from Frost & Sullivan Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry, finds that the market for water and wastewater treatment equipment in the pharmaceutical industry earned revenues of $0.69 billion in 2010 and estimates this to reach $1.25 billion in 2017.
“The most important factor driving growth is the emergence of Asian countries such as India and China as key manufacturing hubs for generic drugs and APIs,” notes a Senior Research Analyst of Frost & Sullivan. “India has over 100 FDA approved drug manufacturing facilities - the highest for any country outside USA.”
The Asian market for water and wastewater treatment equipment in the pharmaceutical industry is expected to grow at a compound annual growth rate of 16.5 per cent from 2010 to 2017. Pharmaceutical companies in North America and Europe are outsourcing certain portions of the drug production process to Asian countries and are keen to focus more on research and drug development. This move could reduce the number of pharmaceutical production facilities in these regions in the future.
“In North America and Europe, the replacement and refurbishment segment are anticipated to offer more potential,” remarks the Senior Research Analyst. “With many countries in these regions outsourcing their operations to Asian countries the water and wastewater treatment equipment market in these regions is expected to grow at the rate of around 5-6% annually.”
In North America and Europe, effluent discharge standards for pharmaceutical production facilities are set to become more stringent in the future.
“Strict effluent discharge standards will force pharmaceutical production facilities to adopt advanced treatment technologies and also focus on sustainable technologies that would facilitate the generation of energy from their wastewater,”
If you are interested in more information on this study, please send an e-mail with your contact details to Chiara Carella, Corporate Communications, at chiara.carella@
Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Pharmaceutical Industry is part of the Environmental Growth Partnership Services programme, which also includes research in the following markets: Global Water Market Outlook: Strategic Analysis of Water and Wastewater Management in the Power Industry, Growth Opportunities in the Polish Waste Management Market, Western European Water and Wastewater Utilities Market and European Waste Recycling Market, among others. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
Corporate Communications – Europe
P: +44 (0) 20 7343 8314
M: +44 (0) 753 3017689